{"mainPropery":{"diseaseId":12757,"diseaseName":"Acute myeloid leukemia ","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/12757/acute-myeloid-leukemia","synonyms":["Acute myelogenous leukemia"],"synonyms-with-source":[{"name":"Acute myelogenous leukemia","source":"OrphaData.Org"}],"identifiers":[{"identifierType":"OMIM","identifierId":"601626"},{"identifierType":"ORPHANET","identifierId":"519"}]},"diseaseCategories":[],"organizations":[{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/601626' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Acute%20myeloid%20leukemia%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Acute myeloid leukemia . Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":102,"resourceId":120,"resourceName":"American Cancer Society","descriptionText":"The <a href='http://www.cancer.org/cancer/leukemia-acutemyeloidaml/' target='_blank'>American Cancer Society</a> provides information on Acute myeloid leukemia . Please click on the link to access this resource.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":775,"resourceId":1860,"resourceName":"Mayo Clinic","descriptionText":"<a href='http://www.mayoclinic.org/diseases-conditions/acute-myelogenous-leukemia/basics/definition/con-20043431' target='_blank'>Mayo Clinic</a> has an information page on Acute myeloid leukemia .","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='https://www.nlm.nih.gov/medlineplus/ency/article/000542.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/197802-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=519' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:601626' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":9621,"questionText":"What is acute myeloid leukemia?","answerText":"<strong>Acute myeloid leukemia (AML)</strong> is a <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45333\" target=\"_blank\">cancer</a> that affects the blood and <a href=\"https://www.nlm.nih.gov/medlineplus/bonemarrowdiseases.html\" target=\"_blank\">bone marrow</a>. Conditions are generally called \"acute\" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003088.htm\" target=\"_blank\">fatigue</a>; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential <a href=\"http://emedicine.medscape.com/article/197802-overview#a4\" target=\"_blank\">causes</a> of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">chemotherapy</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">bone marrow transplant</a> and/or other drug therapy.[9899][9898]","dateModified":"2015-10-29T16:29:00"},"basicQuestions":[],"references":[{"referenceId":9555,"authors":"Schiffer CA & Anastasi J","articleTitle":"Classification of acute myeloid leukemia","bookWebsiteJournalTitle":"UpToDate","date":"October 30, 2013","volume":"","pages":"","url":"http://www.uptodate.com/contents/classification-of-acute-myeloid-leukemia","dateAccessed":"2015-08-27T00:00:00","authors2":"","placeOfPublication":"","publisher":""}],"relatedDiseases":[{"relatedDiseaseId":12758,"relatedDiseaseName":"Acute myeloid leukemia with recurrent genetic anomaly","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":12761,"relatedDiseaseName":"AML with myelodysplasia-related features ","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":8226,"relatedDiseaseName":"Myeloid leukemia","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":12764,"relatedDiseaseName":"Myeloid proliferations related to Down syndrome","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":12763,"relatedDiseaseName":"Myeloid sarcoma","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":12762,"relatedDiseaseName":"Therapy related acute myeloid leukemia and myelodysplastic syndrome","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":12760,"relatedDiseaseName":"Unclassified acute myeloid leukemia ","relation":"Child","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":9970,"phenoTypeName":"Acute myeloid leukemia","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":746,"genericName":"Glasdegib","tradeName":"Daurismo","tradeLink":"https://www.daurismo.com/","manufacturer":"","sponsor":"Pfizer, Inc.","indication":"November 2018, glasdegib (Daurismo) was approved in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.","drugInformationLink":"","medlinePlusLink":""},{"productId":690,"genericName":"Enasidenib","tradeName":"Idhifa","tradeLink":"http://www.idhifa.com/","manufacturer":"","sponsor":"Celgene Corporation","indication":"Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/idhifa","medlinePlusLink":"https://medlineplus.gov/news/fullstory_167534.html"},{"productId":494,"genericName":"Gemtuzumab ozogamicin","tradeName":"Mylotarg","tradeLink":"https://www.mylotarg.com/","manufacturer":"","sponsor":"Wyeth Pharmaceuticals, Inc., a Pfizer Company","indication":"Mylotargâ„¢ is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/mylotarg","medlinePlusLink":"https://medlineplus.gov/news/fullstory_168160.html"},{"productId":677,"genericName":"Midostaurin","tradeName":"Rydapt","tradeLink":"https://www.us.rydapt.com/","manufacturer":"","sponsor":"Novartis Pharmaceuticals Corporation","indication":"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/rydapt","medlinePlusLink":"https://medlineplus.gov/news/fullstory_165033.html"},{"productId":728,"genericName":"Ivosidenib","tradeName":"Tibsovo","tradeLink":"https://www.tibsovo.com/","manufacturer":"","sponsor":"Agios Pharmaceuticals, Inc","indication":"July 20, 2018, ivosidenib (Tibsovo) was approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.","drugInformationLink":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b6d8ae8-bac8-4e1b-b1b4-7f9665e62de5","medlinePlusLink":""},{"productId":747,"genericName":"Venetoclax","tradeName":"Venclexta","tradeLink":"https://www.venclexta.com/","manufacturer":"","sponsor":"AbbVie Inc.","indication":"November 2018, venetoclax (Venclexta) was approved in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/venclexta","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a616028.html"},{"productId":689,"genericName":"Cytarabine and daunorubicin liposome injection","tradeName":"Vyxeos","tradeLink":"https://vyxeos.com/","manufacturer":"","sponsor":"Celator Pharmaceuticals, Inc.","indication":"Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/vyxeos","medlinePlusLink":"https://medlineplus.gov/news/fullstory_167596.html"},{"productId":749,"genericName":"Gilteritinib","tradeName":"Xospata","tradeLink":"http://xospata.com/","manufacturer":"","sponsor":"Astellas Pharma US, Inc.","indication":"November 2018, gilteritinib (Xospata) was approved for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.","drugInformationLink":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383","medlinePlusLink":""}],"EncodedName":"Acute_myeloid_leukemia_"}